Geron stocks.

Looking at Geron's most recent earnings report, as of June 30, 2023, the company had $400.2M in cash and equivalents. In Q2 2023, Geron received $17.8M from cash exercises of warrants and may ...Geron Stock Ownership FAQ. Who owns Geron? Geron (NASDAQ: GERN) is owned by 68.31% institutional shareholders, 1.21% Geron insiders, and 30.48% retail investors. Ra Capital Management LP is the largest individual Geron shareholder, owning 46.20M shares representing 8.51% of the company.Goldman Sachs Upgrades Geron to Buy From Neutral, Price Target is $4. Sep. 12. MT. Goldman Sachs Initiates Geron at Neutral With $3 Price Target. Mar. 28. MT. Needham Adjusts Price Target on Geron to $4 From $3, Maintains Buy Rating.What is Geron's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Geron stock is Buy based on the current 3 buy ratings for GERN. The average twelve-month price prediction for Geron is $4.75 with a high price target of $6.00 and a low price target of $4.00.

6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. Volatility Over Time: GERN's weekly volatility (8%) has been stable over the past year.

Shares of Geron ( GERN -4.48%), a clinical-stage biotech company, were up more than 30% this week before CEO John A. Scarlett's scheduled appearance at the Needham Virtual Healthcare Conference on ...

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better . This article What's Going On With Geron Stock Today ...To: All persons who purchased Geron Corporation (“Geron”) common stock during the period from March 19, 2018, to September 26, 2018, inclusive (the “Class Period”), and who were damaged ...Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better . This article What's Going On With Geron Stock Today ...Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ...Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. [2] [3] They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. [4] The company was incorporated in 1990 and began doing business in 1992.

Dec 1, 2023 · Dollar Volume Sold Short. $86.29 million. Short Interest Ratio / Days to Cover. 7.9. Last Record Date. November 15, 2023. Outstanding Shares.

Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, …

Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 11, 8:15AM CDT . Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?17 août 2023 ... The stock options were granted on August 16, 2023 at an exercise price of $2.70 per share, which is equal to the closing price of Geron common ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Geron Corp. GERN (U.S.: Nasdaq) Overview News Geron Corp. No significant news for in the past two years. Key Stock Data Shares Sold Short 44.48 M Change from Last -1.43% Percent of Float...Geron Corp. (GERN) and CTI Bio (CTIC) were among notable gainers in the blood cancer space after leaked data for multiple myeloma therapy Carvykti . Read more here.Aug 22, 2023 · Geron Corporation ( NASDAQ: GERN) announced Tuesday that the U.S. FDA accepted its marketing application for the blood cancer therapy imetelstat, under standard review with a Prescription Drug ... Get Geron Corp (GERN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Geron Corporation is a late-stage biopharmaceutical ...

Feb 2, 2023 · GERN - Free Report) closed at $3.34 in the latest trading session, marking a -1.18% move from the prior day. This move lagged the S&P 500's daily gain of 1.47%. Elsewhere, the Dow lost 0.11% ... The stock price of GERN is 2.00 while Geron 20-day SMA is 1.87, which makes it a Buy. Geron 50-day simple moving average is 1.95 while GERN share price is 2.00, making it a Buy technically. GERN stock price is 2.00 and Geron 200-day simple moving average is 2.59, creating a Sell signal.A high-level overview of Geron Corporation (GERN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Jun 7, 2023 · Beatty covers the Healthcare sector, focusing on stocks such as Leap Therapeutics, Arrowhead Pharmaceuticals, and Geron. According to TipRanks , Beatty has an average return of 9.4% and a 49.70% ... Geron Corp. (NASDAQ: GERN)’s stock price has gone decline by -4.52 in comparison to its previous close of 1.99, however, the company has experienced a -0.52% decrease in its stock price over the last five trading days. Business Wire reported 2023-11-07 that FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today […]

il y a 13 heures ... Geron is a late-stage clinical biopharmaceutical company pursuing ... Stocks Could Thrive Under 'Higher for Longer' Interest Rates. Sarah ...

Cytokinetics, Geron, and Sangamo are still seeking their first drug approval. Adam Pardee. By Ron Leuty – Senior Reporter, San Francisco Business Times. ... it saw its stock shoot up by a third.Wuchan Zhongda Yuantong Industrial Group Co., Ltd. and Wuchan Zhongda (Zhejiang) Industrial Investment Co., Ltd. signed an agreement to acquire a 29% stake in Geron Co.,Ltd (SZSE:002722) from On Fu International (HK) Investment Limited and Nantong Geron Holdings Co., Ltd. for CNY 1 billion on January 4, 2022.Geron Corporation is a late-stage biopharmaceutical company. The Company is focused on the development and commercialization of imetelstat, a therapeutic for hematologic malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology.May 10, 2023 · Summary. Geron will report Q1 2023 earnings this Thursday 11th May. The company may be close to winning a first FDA approval for a drug in its >30-year history. Imetelstat is a differentiated drug ... The resulting dilution - the share count increased from 327.6m shares to 381m shares, or by ~16%, may explain why Geron stock quickly fell in value, erasing most of the gains triggered by the ...Goldman Sachs has upgraded Geron Corporation (NASDAQ:GERN) to Buy from Neutral, with a price target of $4.. Recently, the FDA assigned a standard review and a Prescription Drug User Fee Act (PDUFA ...Geron stock rises after pricing $198M securities offering SA News Fri, Jan. 06 136 Comments. Geron dips 8.5% on $175M public offering SA News Wed, Jan. 04 28 Comments.

... Geron may pay the purchase price of products by delivery of shares of Geron's Common Stock (the “Shares”). THE PARTIES AGREE AS FOLLOWS: 1. ISSUANCE OF ...

Geron Corporation ( NASDAQ: GERN) has been a broadly upbeat stock since January, when it announced IMerge Phase 3 data in lower-risk myelodysplastic syndromes ('MDS'). The data, which I covered in ...

Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call Transcript November 2, 2023 Geron Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good ...Geron Corporation (GERN) Stock Price, Quote & News - Stock Analysis 1.93 -0.02 (-1.03%) At close: Nov 30, 2023, 4:00 PM 1.92 -0.01 (-0.52%) After-hours: Nov …What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...Sep 12, 2023 · Geron Corporation ( NASDAQ: GERN) added ~9% on Tuesday in the morning hours after Goldman Sachs upgraded the biotech to Buy from Neutral, citing a potential FDA approval for its blood cancer ... Stock. Equities. Stock Geron Corporation - Nasdaq. Geron Corporation (GERN.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock …13 fév. 2023 ... Geron Corporation is expected to launch its first marketed drug in 2024. Idexx Laboratories has increased revenue steadily over the years. While ...Hailshadow/iStock via Getty Images. Geron Corporation ( NASDAQ: GERN) announced on Monday new data from its Phase 3 portion of the Phase 2/3 IMerge trial for lead candidate imetelstat in ...Find the latest Geron Corporation (GERN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Geron Corp. () Stock Market info Recommendations: Buy or sell Geron stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Geron share forecasts, stock quote and buy / sell signals below.According to present data Geron's GERN shares and potentially its market environment have been in bearish cycle last 12 …Geron Corporation Common Stock (GERN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Jan 11, 2023 · Clinical-stage biotech Geron Corporation ( NASDAQ: GERN) announced several recent additions to the company’s senior commercial leadership on Wednesday ahead of the planned launch of its blood ...

3 oct. 2023 ... Key Insights Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their...On November 2, Geron will be reporting earnings from the last quarter. Wall Street analysts expect Geron will be reporting losses per share of $0.097. Watch Geron stock price move in real-time ...Geron (GERN 1.03%) Q1 ... 10 stocks we like better than Geron When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...Instagram:https://instagram. is forex trading legittop workers compensation insurance companies in californiaon holding agftnt share FOSTER CITY, Calif., November 16, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to ... nvda shortstock quote epm John Scarlett GERN stock SEC Form 4 insiders trading. John has made over 2 trades of the Geron stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,340,000 units of GERN stock worth $2,010,000 on 8 February 2023.. The largest trade he's ever made was exercising 1,340,000 units of Geron stock …Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ... penny stock brokerage Geron Corp GERN Morningstar Rating Unlock Stock XNAS Rating as of Dec 1, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance...Dec 1, 2023